Outpace Bio raises $30M Series A to develop custom T cell therapies, partners with Lyell Immunopharma
Seattle startup Outpace Bio raised $30 million in a Series A to develop software and hardware for designing custom cell- and gene-based therapies, initially targeting T cell treatments for solid tumors. The 18-person company, led by co-founder and CEO Marc Lajoie, also announced a partnership with Lyell Immunopharma and counts ARTIS Ventures and Lyell among its investors.